Deleterious myocardial consequences induced by intermittent hypoxia are reversed by erythropoietin

Respiratory Physiology and Neurobiology

Volumn 156, Issue 3, 2007, Pages 362-369

  Ramond, A ^a   Ribuot, C ^a   Levy P ^a   Joyeux Faure, M ^a  

^a University Grenoble Alpes   (France)

Author keywords

Erythropoietin; Infarction; Intermittent hypoxia; Myocardial ischemia reperfusion; Rat

Indexed keywords

NITRIC OXIDE; RECOMBINANT ERYTHROPOIETIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; HEART INFARCTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE CONTRACTILITY; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART PROTECTION; HEART RATE; HEMODYNAMIC PARAMETERS; HYPOXIA; ISOLATED HEART; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANOXIA; CORONARY CIRCULATION; ERYTHROPOIETIN, RECOMBINANT; HEART DISEASES; HEART RATE; MALE; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; RATS; RATS, WISTAR; VENTRICULAR FUNCTION, LEFT;

EID: 33947392194     PISSN: 15699048     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.resp.2006.10.011     Document Type: Article

References (35)

1. Baines C.P., Zhang J., Wang G.W., Zheng Y.T., Xiu J.X., Cardwell E.M., Bolli R., and Ping P. Mitochondrial PKCepsilon and MAPK form signaling modules in the murine heart: enhanced mitochondrial PKCepsilon-MAPK interactions and differential MAPK activation in PKCepsilon-induced cardioprotection. Circ. Res. 90 (2002) 390-397
2. Beguin P.C., Joyeux-Faure M., Godin-Ribuot D., Levy P., and Ribuot C. Acute intermittent hypoxia improves rat myocardium tolerance to ischemia. J. Appl. Physiol. 99 (2005) 1064-1069
3. Bernaudin M., Marti H.H., Roussel S., Divoux D., Nouvelot A., MacKenzie E.T., and Petit E. A potential role for erythropoietin in focal permanent cerebral ischemia in mice. J. Cereb. Blood Flow Metab. 19 (1999) 643-651
4. Bogoyevitch M.A. An update on the cardiac effects of erythropoietin cardioprotection by erythropoietin and the lessons learnt from studies in neuroprotection. Cardiovasc. Res. 63 (2004) 208-216
5. Brines M.L., Ghezzi P., Keenan S., Agnello D., de Lanerolle N.C., Cerami C., Itri L.M., and Cerami A. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 10526-10531
6. Bullard A.J., Govewalla P., and Yellon D.M. Erythropoietin protects the myocardium against reperfusion injury in vitro and in vivo. Basic Res. Cardiol. 100 (2005) 397-403
7. Bullard A.J., and Yellon D.M. Chronic erythropoietin treatment limits infarct-size in the myocardium in vitro. Cardiovasc. Drugs Ther. 19 (2005) 333-336
8. Cai Z., Manalo D.J., Wei G., Rodriguez E.R., Fox-Talbot K., Lu H., Zweier J.L., and Semenza G.L. Hearts from rodents exposed to intermittent hypoxia or erythropoietin are protected against ischemia-reperfusion injury. Circulation 108 (2003) 79-85
9. Cai Z., and Semenza G.L. Phosphatidylinositol-3-kinase signaling is required for erythropoietin-mediated acute protection against myocardial ischemia/reperfusion injury. Circulation 109 (2004) 2050-2053
10. Calvillo L., Latini R., Kajstura J., Leri A., Anversa P., Ghezzi P., Salio M., Cerami A., and Brines M. Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodelling. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 4802-4806
11. Cole W.C., McPherson C.D., and Sontag D. ATP-regulated K+ channels protect the myocardium against ischemia/reperfusion damage. Circ. Res. 69 (1991) 571-581
12. Ehrenreich H., Hasselblatt M., Dembowski C., Cepek L., Lewczuk P., Stiefel M., Rustenbeck H.H., Breiter N., Jacob S., Knerlich F., Bohn M., Poser W., Ruther E., Kochen M., Gefeller O., Gleiter C., Wessel T.C., De Ryck M., Itri L., Prange H., Cerami A., Brines M., and Siren A.L. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol. Med. 8 (2002) 495-505
13. Fletcher E.C. Invited review: physiological consequences of intermittent hypoxia-systemic blood pressure. J. Appl. Physiol. 90 (2001) 1600-1605
14. Hausenloy D.J., and Yellon D.M. New directions for protecting the heart against ischaemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway. Cardiovasc. Res. 61 (2004) 448-460
15. Hirata A., Minamino T., Asanuma H., Sanada S., Fujita M., Tsukamoto O., Wakeno M., Myoishi M., Okada K., Koyama H., Komamura K., Takashima S., Shinozaki Y., Mori H., Tomoike H., Hori M., and Kitakaze M. Erythropoietin just before reperfusion reduces both lethal arrhythmias and infarct size via the phosphatidylinositol-3 kinase-dependent pathway in canine hearts. Cardiovasc. Drugs Ther. 19 (2005) 33-40
16. Ito K., Sato T., and Arita M. Protein kinase C isoform-dependent modulation of ATP-sensitive K+ channels during reoxygenation in guinea-pig ventricular myocytes. J. Physiol. 532 (2001) 165-174
17. Joyeux-Faure M., Godin-Ribuot D., and Ribuot C. Erythropoietin and myocardial protection: what's new?. Fundam. Clin. Pharmacol. 19 (2005) 439-446
18. Joyeux-Faure M., Ramond A., Beguin P.C., Belaidi E., Godin-Ribuot D., and Ribuot C. Early pharmacological preconditioning by erythropoietin mediated by inducible NOS and mitochondrial ATP-dependent potassium channels in the rat heart. Fundam. Clin. Pharmacol. 20 (2006) 51-56
19. Joyeux M., Arnaud C., Godin-Ribuot D., Demenge P., Lamontagne D., and Ribuot C. Endocannabinoids are implicated in the infarct size-reducing effect conferred by heat stress preconditioning in isolated rat hearts. Cardiovasc. Res. 55 (2002) 619-625
20. Joyeux M., Godin-Ribuot D., and Ribuot C. Resistance to myocardial infarction induced by heat stress and the effect of ATP-sensitive potassium channel blockade in the rat isolated heart. Br. J. Pharmacol. 123 (1998) 1085-1088
21. Juul S.E., Yachnis A.T., and Christensen R.D. Tissue distribution of erythropoietin and erythropoietin receptor in the developing human fetus. Early Hum. Dev. 52 (1998) 235-249
22. Klingmuller U. The role of tyrosine phosphorylation in proliferation and maturation of erythroid progenitor cells-signals emanating from the erythropoietin receptor. Eur. J. Biochem. 249 (1997) 637-647
23. Noma A. ATP-regulated K+ channels in cardiac muscle. Nature 305 (1983) 147-148
24. Parsa C.J., Kim J., Riel R.U., Pascal L.S., Thompson R.B., Petrofski J.A., Matsumoto A., Stamler J.S., and Koch W.J. Cardioprotective effects of erythropoietin in the reperfused ischemic heart: a potential role for cardiac fibroblasts. J. Biol. Chem. 279 (2004) 20655-20662
25. Partinen M., and Guilleminault C. Daytime sleepiness and vascular morbidity at seven-year follow-up in obstructive sleep apnea patients. Chest 97 (1990) 27-32
26. Sadamoto Y., Igase K., Sakanaka M., Sato K., Otsuka H., Sakaki S., Masuda S., and Sasaki R. Erythropoietin prevents place navigation disability and cortical infarction in rats with permanent occlusion of the middle cerebral artery. Biochem. Biophys. Res. Commun. 253 (1998) 26-32
27. Santhanam A.V., Smith L.A., Nath K.A., and Katusic Z.S. In vivo stimulatory effect of erythropoietin on endothelial nitric oxide synthase in cerebral arteries. Am. J. Physiol. Heart Circ. Physiol. (2006)
28. Shi Y., Rafiee P., Su J., Pritchard Jr. K.A., Tweddell J.S., and Baker J.E. Acute cardioprotective effects of erythropoietin in infant rabbits are mediated by activation of protein kinases and potassium channels. Basic Res. Cardiol. 99 (2004) 173-182
29. Stoohs R., and Guilleminault C. Cardiovascular changes associated with obstructive sleep apnea syndrome. J. Appl. Physiol. 72 (1992) 583-589
30. Tramontano A.F., Muniyappa R., Black A.D., Blendea M.C., Cohen I., Deng L., Sowers J.R., Cutaia M.V., and El-Sherif N. Erythropoietin protects cardiac myocytes from hypoxia-induced apoptosis through an Akt-dependent pathway. Biochem. Biophys. Res. Commun. 308 (2003) 990-994
31. van der Meer P., Lipsic E., Henning R.H., de Boer R.A., Suurmeijer A.J., van Veldhuisen D.J., and van Gilst W.H. Erythropoietin improves left ventricular function and coronary flow in an experimental model of ischemia-reperfusion injury. Eur. J. Heart. Fail. 6 (2004) 853-859
32. Williams R.S., and Benjamin I.J. Protective responses in the ischemic myocardium. J. Clin. Invest. 106 (2000) 813-818
33. Wright G.L., Hanlon P., Amin K., Steenbergen C., Murphy E., and Arcasoy M.O. Erythropoietin receptor expression in adult rat cardiomyocytes is associated with an acute cardioprotective effect for recombinant erythropoietin during ischemia-reperfusion injury. FASEB J. 18 (2004) 1031-1033
34. Wu X.C., Johns E.J., and Richards N.T. Relationship between erythropoietin and nitric oxide in the contraction of rat renal arcuate arteries and human umbilical vein endothelial cells. Clin. Sci. (Lond.) 97 (1999) 413-419
35. Yellon D.M., and Baxter G.F. A "second window of protection" or delayed preconditioning phenomenon: future horizons for myocardial protection?. J. Mol. Cell. Cardiol. 27 (1995) 1023-1034